BE Biosol Capabilities Update August 2026: CPHI Special Edition

BE BioSol is the biologics CDMO business of Biological E. Limited, combining more than 70 years of biopharmaceutical manufacturing experience with a growing, integrated development and manufacturing platform for global biopharma partners.

With a strong track record supporting regulated markets and long-standing relationships with leading pharmaceutical companies, BE BioSol provides development, analytical, technology transfer, and commercial manufacturing solutions across biologics and vaccines.

Our established sterile drug product capabilities include liquid and lyophilized vials, prefilled syringes, and cartridges, supported by significant available capacity for new partner programs. BE BioSol is also investing in expanded drug substance, drug product, and R&D infrastructure to create an increasingly integrated development-to-commercial platform.

Backed by Biological E.’s global operating experience, quality culture, and manufacturing scale, BE BioSol offers partners a compelling combination of scientific expertise, reliable execution, competitive economics, and capacity available today.

Built on a legacy. Focused on your success.